Abstract:PDF file - 818K, Supplemental Figure S1 (A) A 3D Principal component analysis (PCA) plot of the miRNA data that characterizes the trends exhibited by the expression profiles of pancreatic cancer (PC, purple), pancreatic neuroendocrine tumor (NET, green), chronic pancreatitis (CP, red)), healthy controls (N, blue). Each dot represents a sample and each color represents the type of the sample. (B) VENN diagram showing significantly elevated miRNAs (fold-change less than or equal to 2 and p<0.05) in pancreatic cancer (PC) compared to three control groups (NET, CP, and N). Supplemental Figure S2 Reproducibility of Taqman miRNA microarray. (A) A serum sample was analyzed in duplicate and the correlation was determined using Spearman test. (B) The effects of pre-amplification on serum miR-1290 levels by Taqman RT-PCR. Supplemental Figure S3 Validation of elevated miRNAs in serum from patients with pancreatic cancer. Levels of selected serum microRNAs were compared in an independent set of cases and controls including patients with pancreatic cancer (n=41) compared to patients with pancreatic neuroendocrine tumor (NET) (n=18) and chronic pancreatitis (CP) (n=35), normal controls (N) (n=19), and the combined from of non-malignant controls including chronic pancreatitis and normal controls (CN) (n=54), and non-pancreatic cancer control including pancreatic neuroendocrine tumor, chronic pancreatitis, and normal controls (NCN) (n=72) using Taqman real-time PCR. Boxes represent the inter-quartile range and the line indicates the median value. Error bars indicate the 90th and 10th percentiles. MiR-16 was used as reference gene for normalization. Mann-Whitney was used to compare groups. 2 Supplemental Figure S4 The effects of miR-1290 on pancreatic cancer cell proliferation and invasion. (A). The expression levels of miR-1290 were measured in miR-1290 mimic-transfected AsPC1 and Panc5.04 and miR-1290 inhibitor-transfected Panc10.05 and Panc198 cell lines, respectively. (B). Cell lines expressing low levels of miR 1290 (AsPC1 and Panc5.04) were transfected with miR-1290 mimic and cell lines with high miR-1290 (Panc10.05 and Panc198) were transfected with a miR-1290 inhibitor and miRNA controls, and cell growth was determined using MTS assay, respectively. Data are mean +/- SD of 5 replicates and are representative of two independent experiments. (C). The invasive potential of miR-1290 was determined using a chamber matrigel invasion assay in the same cell lines treated in the same way. Data are mean +/- SD of triplicates and are representative of two independent experiments. Representative photographs of invasion assays were shown (D). Original magnification, 20x.

Supplementary Figure 5 from Pancreatic Cancers Epigenetically Silence SIP1 and Hypomethylate and Overexpress Mir-200A/200b in Association with Elevated Circulating Mir-200A and Mir-200B Levels

Pancreatic Cancers Epigenetically Silence <i>SIP1</i> and Hypomethylate and Overexpress <i>miR-200a/200b</i> in Association with Elevated Circulating <i>miR-200a</i> and <i>miR-200b</i> Levels

Exosome-derived Mir-182-5p Promoted Cholangiocarcinoma Progression and Vasculogenesis by Regulating ADK/SEMA5a/PI3K Pathway

Abstract 4094: Pancreatic cancers epigenetically silence ZFHX1B, hypomethylate and overexpress miR-200a/−200b, in association with elevated circulating miR-200a and miR-200b levels

Supplementary Figure 1 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Figure 4 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

Supplementary Figure 5 from DNA Methylation-Mediated Repression of Mir-886-3p Predicts Poor Outcome of Human Small Cell Lung Cancer

MicroRNA Expression Profiling of Pancreatic Cancer Cell Line L3.6p1 Following B7-H4 Knockdown

Supplementary Figure S5 from Epigenetic Silencing of Mir-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>helicobacter Pylori</i>–induced Gastric Carcinogenesis

Supplementary Figure 1 from Mir-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non–Small Cell Lung Cancer

Supplementary Figure S2 from Epigenetic Silencing of Mir-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote Helicobacter Pylori–induced Gastric Carcinogenesis

Supplementary Figure 2 from Mir-205 Targets PTEN and PHLPP2 to Augment AKT Signaling and Drive Malignant Phenotypes in Non–Small Cell Lung Cancer

Supplementary Figure S3 from Epigenetic Silencing of Mir-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>helicobacter Pylori</i>–induced Gastric Carcinogenesis

Supplementary Figure S4 from Epigenetic Silencing of miR-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>Helicobacter pylori</i>–Induced Gastric Carcinogenesis

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Data from Mirna-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3

Supplementary Figures 1-4 from MicroRNA Array Analysis Finds Elevated Serum Mir-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls

Supplementary Figure 1 from Mir200c Attenuates P-gp–Mediated MDR and Metastasis by Targeting JNK2/c-Jun Signaling Pathway in Colorectal Cancer

Mir-615-5p is Epigenetically Inactivated and Functions As a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma

Supplementary Figure Legends from Epigenetic Silencing of Mir-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>helicobacter Pylori</i>–induced Gastric Carcinogenesis

Figure S1 from Hypoxic Tumor-Derived Exosomal Mir-301A Mediates M2 Macrophage Polarization Via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis